




Searching News Database: Pluristem Therapeutics
HSMN NewsFeed - 28 Jun 2018
Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors
Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors
HSMN NewsFeed - 12 Aug 2015
Japan Grants Safety Clearance to Pluristem's PLX-PAD Cells for Use in Clinical Trials
Japan Grants Safety Clearance to Pluristem's PLX-PAD Cells for Use in Clinical Trials
HSMN NewsFeed - 5 Feb 2014
Pluristem Strengthens Executive Team; Announces Senior Executive Appointments
Pluristem Strengthens Executive Team; Announces Senior Executive Appointments
HSMN NewsFeed - 21 Jan 2014
Pluristem's Phase I/II Muscle Injury Trial Successfully Meets Primary Safety & Efficacy Endpoints
Pluristem's Phase I/II Muscle Injury Trial Successfully Meets Primary Safety & Efficacy Endpoints
HSMN NewsFeed - 18 Apr 2013
Pluristem Expands PLX Product Portfolio in Orthopedics and Sports Medicine
Pluristem Expands PLX Product Portfolio in Orthopedics and Sports Medicine
HSMN NewsFeed - 5 Sep 2012
Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use
Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use
HSMN NewsFeed - 16 Jun 2009
Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
HSMN NewsFeed - 8 Jan 2008
Pluristem Announces Second Clinical Indication Revascularization Effect After PLX-PAD Therapy
Pluristem Announces Second Clinical Indication Revascularization Effect After PLX-PAD Therapy